Unveiling a suspected dupilumab-induced neuropathy in pediatric eosinophilic esophagitis

Affiliations

¹ Pediatric Gastroenterology, Hepatology and Nutrition, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
² Neurology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
³ Dermatology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
⁴ Allergy, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.

Case Reports

Hugo Gagnon et al. Pediatr Allergy Immunol. 2024 Aug.

. 2024 Aug;35(8):e14217.

doi: 10.1111/pai.14217.

¹ Pediatric Gastroenterology, Hepatology and Nutrition, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
² Neurology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
³ Dermatology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
⁴ Allergy, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.

No abstract available

Keywords: case report; dupilumab; eosinophilic; eosinophilic esophagitis; esophagitis; neuropathy; pediatric.

References

1. Hahn JW, Lee K, Shin JI, et al. Global incidence and prevalence of eosinophilic esophagitis, 1976–2022: a systematic review and meta‐analysis. Clin Gastroenterol Hepatol. 2023;21:3270‐3284.e77.
1. Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111‐122.e10.
1. FDA approves first treatment for eosinophilic esophagitis, a chronic immune disorder. 2022 https://www.fda.gov/news‐events/press‐announcements/fda‐approves‐first‐t...
1. Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double‐blind, randomised, placebo‐controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):990‐1004.
1. Dupixent FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE). 2024 https://www.sanofi.com/en/media‐room/press‐releases/2024/2024‐01‐25‐19‐3...